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1. Introduction 
As presented in the previous chapter, excessive exposure to endogenous or exogenous 
glucocorticoids (GCs) can disrupt glucose homeostasis in health individuals leading to 
glucose intolerance and/or insulin resistance (IR), and also aggravates the glucose 
metabolism in type 2 diabetic patients. In this context, we aim, in this chapter, to present and 
discuss the adaptive compensations in three levels: structural, functional and molecular - of 
the endocrine pancreas in response to the GC-induced IR and glucose intolerance that are 
required to maintain glycemia at physiological or near to physiological values. We will 
bring a comprehensive summary on experimental and clinical investigations performed in 
humans, rats and mice. Species differences will receive a special focus since the literature 
regarding humans, rats and mice responses to GC treatment indicates that there are species 
differences in both response to and sensitivity towards CGs. 
2. Effect of glucocorticoids on the endocrine pancreas 
GC hormones are secreted by the adrenal cortex under control of the HPA axis. This class of 
hormones plays an important role on energy homeostasis by modulating glucose, lipid and 
protein metabolism. The HPA axis may receive several inputs during some stressful 
conditions, such as fasting, physical activities as well as emotional episodes. In such 
conditions, the physiological GC actions guarantee adequate substrate supply for oxidative 
metabolism by increasing hepatic glucose production, lipolysis and proteolysis (Andrews & 
Walker, 1999). 
Alterations in peripheral insulin sensitivity are reciprocally related to pancreatic islet 
function, in that insulin secretion is initially adaptively increased in response to conditions 
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of IR (e.g., obesity, pregnancy, pre-diabetes) (Kahn et al., 1993). As GCs induce IR, pancreatic 
β-cells initially also increase their insulin secretion capacity in response to GC treatment 
(Beard et al., 1984; Nicod et al., 2003; Ahrén, 2008; Rafacho et al., 2008; Rafacho et al., 2010). 
However, it is also known that GCs, by direct effects, can cause pancreatic β-cell 
dysfunction, which leads to attenuated GSIS (Lambillotte et al., 1997; Jeong et al., 2001; 
Ullrich et al., 2005; Zawalich et al., 2006; Roma et al., 2011). The crucial point is that, at least 
during short (2 to 15 days) periods of treatment, the direct negative effects of GCs are not 
reproduced on pancreatic β-cell during in vivo GC administration to normal subjects, and 
the derangement of β-cells during GC treatment seems to depend on predispositions such as 
genetic background (Ogawa et al., 1992), age (Novelli et al., 1999) as well as previous 
glucose intolerance and/or low insulin sensitivity (Wajngot et al., 1992; Ohneda et al., 1993; 
Henriksen et al., 1997; Larsson & Ahren, 1999; Besse et al., 2005). In the next topic, we will 
discuss in detail the endocrine pancreas and glucose homeostasis profile both in human and 
in rodent experimental models of GC treatment. In addition, results of in vitro studies in 
which primary β-cells or insulin-producing cells have been exposed to GCs will be 
discussed. 
2.1. GC treatment and glucose tolerance, insulin sensitivity and β-cell function 
in humans 
2.1.1. Acute GC effects in healthy individuals 
The acute effects of GCs in healthy individuals, as judged by cortisol infusion (Shamoon et 
al., 1980) or by high doses of prednisolone (Kalhan & Adam, 1975; van Raalte et al., 2010), 
seem to be inhibitory for insulin secretion. This is based on the fact that circulating insulin 
levels during fasting state are not altered following GC treatment, despite the increase in 
blood glucose levels. The increase in glycemia is associated with decreased glucose uptake and 
clearance, whereas the rates of endogenous glucose production are unchanged (Shamoon et 
al., 1980). Glucose intolerance is observed during an oral glucose tolerance test (oGTT) in 
healthy individuals receiving a single oral dose of 1 mg dexamethasone (DEX) just prior to 
the oGTT. In the latter, glucose intolerance was also a result of decreased glucose clearance; 
while no differences in endogenous glucose production was observed too (Schneiter & 
Tappy, 1998). Although the literature concerning rapid GC effects on insulin secretion in 
healthy individuals is scarce, it seems that insulin secretion under glucose infusion is 
reduced (Shamoon et al., 1980) or unaltered (Schneiter & Tappy, 1998) in response to a 
glucose challenge, suggesting an acute inhibitory effect of the GCs on β-cells (Kalhan & 
Adam, 1975). It should also be mentioned that adaptive compensation to short GC 
exposures are transitory and usually reversible after discontinuation of steroid treatment 
(van Raalte et al., 2010). 
2.1.2. GC effects during prolonged exposure in healthy individuals 
Treatment of healthy subjects with high doses of DEX (2 to 4 days) or prednisolone (6 to 15 
days) is associated with normoglycemia or modest increase in fasting blood glucose levels 
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concomitant with significantly heightened circulating insulin concentrations during the 
post-absorptive state (Pagano et al., 1983; Beard et al., 1984; Grill et al., 1990; Schneiter & 
Tappy, 1998; Hollingdal et al., 2002; Willi et al., 2002; Nicod et al., 2003; Binnert et al., 2004; 
van Raalte et al., 2010), (see an overview in Table 1). The elevation of insulinemia indicates 
IR, a condition also confirmed after GC treatment (Pagano et al., 1983; Grill et al., 1990; 
Larsson & Ahren, 1999; Hollingdal et al., 2002; Willi et al., 2002; Nicod et al., 2003; Ahrén, 
2008). The modest increase in fasting glycemia may be explained by direct effect of GCs on 
hepatic de novo glucose production or by a reduction of glucose uptake by peripheral tissues 
(e.g., muscle, liver and adipose tissue). In this case, even high levels of insulin (Schneiter & 
Tappy, 1998) are insufficient to compensate for IR evoked by the steroid treatment. 
However, it must be stressed that most studies with GC administration for a short period 
in healthy volunteers do not show fasting hyperglycemia (Nicod et al., 2003; Binnert et al., 
2004; Ahrén, 2008; van Raalte et al., 2010). Under glucose challenging by hyperglycemic-
clamp (Beard et al., 1984; Nicod et al., 2003; Binnert et al., 2004) or an oGTT (Schneiter & 
Tappy, 1998; Hollingdal et al., 2002; Willi et al., 2002), insulin secretion is higher in GC-
treated healthy subjects compared with control individuals. This increase in insulin 
secretion appears to be sufficient to maintain glucose homeostasis (Nicod et al., 2003; 
Binnert et al., 2004; Ahrén, 2008), suggesting that for the period of steroid exposure 
observed in the above studies the islets adjust their insulin release to overcome the IR 
imposed by GC treatment. However, we cannot exclude the possibility that at a more 
prolonged exposure (months or even years as in patients subjected to chronic GC 
therapies) β-cell dysfunction develops in face of sustained IR and/or by direct negative 
effects of GCs on β-cell function/viability resulting in dysregulation of glucose 
homeostasis. 
The increased insulin secretion noted during GC treatment needs not necessarily result from 
a direct GC action on β-cells. This is suggested as several changes, such as in substrates, 
hormones, and/or neural influences that β-cells are exposed to, precluding a clear 
explanation of the factors causing increased islet function. Ahrén (Ahrén, 2008) performed 
an elegant experiment in which healthy women were subjected to oral DEX administration 
in a dose and period that resulted in IR, and insulin hypersecretion in response to arginine 
infusion. After 3 to 6 months, the same volunteers were treated with the same steroid 
regimen, but also received an intravenous infusion of a ganglionic antagonist 
(trimethaphan), which interrupts neural transmission. Arginine-stimulated insulin secretion 
was higher in DEX-treated individuals, as expected, but was markedly inhibited by the 
ganglionic antagonist. These data imply that a stimulus triggered by IR increases the 
parasympathetic tone to the islet β-cells to increase insulin secretion and this may contribute 
to the adaptive hypersecretion of insulin during IR (Ahrén, 2008). Whether this autonomic 
effect involves the classical neuropeptide acetylcholine, or any of the other parasympathetic 
neuropeptides, remains to be investigated (Ahrén, 2008). 
In summary, the product of insulin secretion and peripheral insulin sensitivity, also called 
the disposition index, remains constant in healthy subjects exposed to GC treatment. 
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GC Route Dosing Insulin 
sensitivity (IS) 
Glucose tolerance 
(GT) 
Fasting 
glycemia 
Fasting 
insulinemia 
Insulin 
secretion 
Reference 
Pred Oral 15 mg  b.i.d. 
for 7 d 
Decreased IS Modest 
increase 
Modest 
increase 
----- (Pagano et al., 
1983)  
Dex Oral 3 mg b.i.d. for
 2 1/2 d  
----- Modest 
increase 
Increased Increased (Beard et al., 
1984) 
Dex Oral 3 mg b.i.d. for 
2 1/2 d 
Decreased IS  Increased Increased Varied (Grill et al., 
1990) 
Dex Oral 4 mg for 5 d Decreased IS ----- ----- Increased  (Kautzky-
Willer et al., 
1996) 
Dex Oral 0.5 mg q.d. for 
2 d and 1 mg 
at the 3rd d.  
 Decreased GT Unaltered Increased Increased  (Schneiter & 
Tappy, 1998) 
Pred Oral 15 mg b.i.d. 
for 6 d  
Decreased IS Modest 
increase 
Increased Increased (Hollingdal et 
al., 2002) 
Dex Oral 2 mg b.i.d. for 
4 d 
Decreased IS Modest 
increase  
Increase  
 
Increased (Willi et al., 
2002) 
Dex Oral 0.5 mg q.d. for 
2 d 
Decreased IS Unaltered 
 
Increased  Increased (Nicod et al., 
2003) 
Dex Oral 0.5 mg q.d. for 
2 d and 0.5 
mg at the 3rd d
Decreased IS Unaltered Increased  Increased (Binnert et al., 
2004) 
Dex Oral 3 mg b.i.d. for 
2 1/2 d 
Decreased IS Unaltered Increased 
 
Increased 
 
(Ahrén, 2008) 
Pred Oral 30 mg for 15 d 
 
Decreased IS 
Decreased GT 
Increased  Tendency 
towards 
increase 
 
Decreased 
 
(van Raalte et 
al., 2010) 
b.i.d.; twice a day (from Latin bis in die), d; day, q.d.; four times each day (from Latin quater die 
sumendus), Pred; prednisolone, Dex; dexamethasone, -----; none 
Table 1. Effects of prolonged GC treatment on glucose homeostasis in healthy volunteers. 
2.1.3. GC effects in susceptible subjects 
Administration of GCs to individuals with any degree of susceptibility towards glucose 
intolerance, but still normoglycemic, before treatment with GCs, such as those with low 
insulin sensitivity (Larsson & Ahren, 1999) or with low insulin response to glucose (Wajngot 
et al., 1992), obese women (Besse et al., 2005) and first-degree relatives of patients with type 
2 diabetes mellitus (T2DM) (Henriksen et al., 1997), fails to induce the adaptive islet 
compensation observed in healthy subjects. Thus, in such individuals GC treatment may 
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disrupt glucose homeostasis and cause hyperglycemia. The derangements that contribute to 
glucose intolerance include reduction in glucose-dependent or arginine-induced insulin 
release (Larsson & Ahren, 1999), increased glucose production and decreased glucose 
clearance (Wajngot et al., 1992), and reduction in whole body glucose disposal (Besse et al., 
2005). Therefore, the enhancement in β-cell response, required to accommodate the GC-
induced IR state, is impaired in these subjects. 
2.1.4. Obstacles for the investigation of β-cell function in humans 
The prolonged period of GC therapy utilized in clinical practice may surpass the short 
period used for experimental approaches in human studies that often is restricted to 2-15 
days of GC treatment (van Raalte et al., 2009). Thus, the data from human experimental 
models, although of great relevance, fail to mimic the conditions of clinical practice. 
Elaboration of chronic GC protocols to investigate β-cell function in human volunteers is not 
feasible in consideration of the risk to develop irreversible adverse effects, ethical issues, as 
well as the nature of ex vivo and in vitro tools available for the mechanistic comprehension of 
β-cell function and growth (van Raalte et al., 2009). Yet, patients exhibiting excess of 
endogenous or exogenous GCs generally develop other side effects or altered circulating 
factors that could mask the GC effects on β-cell function (Dessein & Joffe, 2006). 
Taken together, acute GC administration seems to exert an inhibitory effect on insulin 
secretion, while prolonged exposure induces alterations in β-cell function as an adaptive 
compensation to surpass GC-induced IR. However, susceptible subjects are prone to 
develop β-cell dysfunction with subsequent impairment of glucose homeostasis. 
Considering that mechanistic investigations require ex vivo and in vitro approaches, and that 
rodent models exhibit similar responses as humans in terms of insulin secretion and glucose 
homeostasis profile, use of experimental rodent models has been important for 
understanding β-cell function during GC treatments. 
2.2. GC treatment and glucose tolerance, insulin sensitivity and β-cell function 
in rodents  
The effects of GCs on insulin secretion have been assessed in vivo and ex vivo in rats and 
mice and show that the compensatory islet responses in rats are similar to those observed in 
human volunteers. The importance of endogenous GCs was demonstrated in rats (Borelli et 
al., 1982) with bilateral adrenalectomy. These rats exhibit impaired insulin secretion in vivo in 
response to glucose, which is corrected by GC replacement. The endocrine pancreas 
adaptations to GC administration are not similar between rats and mice and for this reason we 
will first discuss the literature obtained with rat models and then proceed to mouse models. 
2.2.1. Acute GC effects in normal rats 
When administered acutely (4 to 6 hours), DEX causes a modest decrease in insulin 
sensitivity (Qi et al., 2004) or increased rate of glucose disappearance (Stojanovska et al., 
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1990). This remains controversial, but at any rate it is accompanied by normoglycemia 
(Stojanovska et al., 1990; Qi et al., 2004) together with normal (Qi et al., 2004) or increased 
plasma insulin values (Stojanovska et al., 1990). These data reveal no deleterious effect of 
DEX on the insulinogenic index (the ratio between insulinemia and glycemia) when the 
steroid is acutely administered in rats. 
2.2.2. Glucose tolerance and insulin sensitivity in GC-treated rats 
The majority of the studies using rat models are performed with prolonged exposure to GCs 
and DEX is the compound preferentially employed. The protocols vary in dose (0.01 to 5 
mg/kg, b.w.), duration (1 day to 8 weeks) and administration route (subcutaneous, 
intramuscular, intraperitoneal, oral), gender, age, and strain (Lee et al., 1989; O'Brien et al., 
1991; Koranyi et al., 1992; Ohneda et al., 1993; Wang et al., 1994; Novelli et al., 1999; Holness 
& Sugden, 2001; Karlsson et al., 2001; Choi et al., 2006; Wierup et al., 2006; Rafacho et al., 
2008; Rafacho et al., 2011) (Table 2). Similar to humans, normal rats treated with DEX had 
decreased peripheral insulin sensitivity. This GC-induced IR is time-, dose- and age-
dependent (Novelli et al., 1999; Rafacho et al., 2008; Rafacho et al., 2011) and is a common 
effect in GC-treated rats. This is supported by the fact that most studies showed fasting 
hyperinsulinemia, an indicator of IR (Lee et al., 1989; Stojanovska et al., 1990; Koranyi et al., 
1992; Novelli et al., 1999; Zakrzewska et al., 1999; Barbera et al., 2001; Holness & Sugden, 
2001; Karlsson et al., 2001; Severino et al., 2002; Choi et al., 2006; Giozzet et al., 2008; Rafacho 
et al., 2008; Rafacho et al., 2010). This rise in circulating insulin concentrations fully 
compensates for peripheral IR in normal rats and prevents any increase in blood glucose 
concentrations (Lee et al., 1989; Koranyi et al., 1992; Ogawa et al., 1992; Novelli et al., 1999; 
Zakrzewska et al., 1999; Barbera et al., 2001; Holness & Sugden, 2001; Severino et al., 2002; 
Choi et al., 2006; Giozzet et al., 2008; Rafacho et al., 2008; Rafacho et al., 2010), except in 
normal elderly rats (Novelli et al., 1999) or when the highest experimental doses (1 mg/kg. 
b.w.) and/or duration (four days or more) of DEX administration are used. However, these 
latter experimental conditions provoke only a slight elevation in blood glucose levels that do 
not exceed an average value of 7.5 mM (Stojanovska et al., 1990; Holness & Sugden, 2001; 
Holness et al., 2005; Rafacho et al., 2008; Rafacho et al., 2010). The glucose tolerance in GC-
treated rats also varies depending on the dose, duration or predisposing factors (e.g., 
pregnancy, obesity and aging) (Novelli et al., 1999; Holness & Sugden, 2001). Normal male 
adult rats receiving 0.1, 0.5 or 1 mg/kg b.w. of DEX for 1 to 3 days do not exhibit glucose 
intolerance during a glucose load; however, when these rats are submitted to 5 days of 
DEX treatment at 1 mg/kg b.w. they become glucose intolerant (Rafacho et al., 2008). Thus, 
for low doses and/or short periods of GC administration, the elevation in insulin secretion 
is sufficient to prevent any derangement in glucose homeostasis. However, for higher 
doses and/or prolonged periods of GC treatment, these normal rats are unable to fully 
compensate for the metabolic demand and glucose intolerance appears, despite the 
marked increase in insulin response to glucose. Whether increased levels of lipids, like 
non-esterified fatty acids (NEFA), contribute to this metabolic perturbation deserves 
investigation, but there is already evidence that increased lipolysis may affect 
insulinogenic index under GC-induced IR in normal rats (Novelli et al., 2008). It is also 
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important to mention that GC-treated elderly rats (Novelli et al., 1999), high-fat diet rats 
(Holness et al., 2005) or pregnant rats (Holness & Sugden, 2001) become intolerant to 
glucose after a sugar challenge that is associated with a decreased insulinogenic index. 
Notably, all above alterations by GC treatment are transitory and normalized after 
discontinuation of steroid administration in healthy rats (Rafacho et al., 2010). 
 
GC R Dosing Insulin 
sensitivity (IS) 
Glucose 
tolerance (GT) 
Fasting 
glycemia 
Fasting 
insulinemia 
Insulin secretion Reference 
Dex ---- 5 µg b.i.d. for 
3 or 4 d in 
male SD  
Decreased IS Modest increase Increased Increased 
 
(Stojanovska 
et al., 1990) 
Dex i.p 2 mg/kg b.w. 
for 7 d in 
female SD  
 -----  ----- ----- Increased 1st 
phase, but not 2nd 
in isolated islets 
(O'Brien et 
al., 1991) 
Dex i.p. 5 mg/kg for  
24 d (male 
and female?) 
Decreased IS in 
normal animals 
Unaltered ----- Increased  
 
(Ogawa et al., 
1992) 
Dex ---- 0.125 mg/kg 
b.w. b.i.d. for 4 
d  in male SD 
----- Unaltered Increased ----- (Koranyi et 
al., 1992) 
Dex s.c. 4 mg/kg b.w. 
for 10 d 
----- 
----- ----- ----- Increased (Wang et al., 
1994) 
Dex s.c. 0,125 mg/kg 
b.w. for 13 d 
in 3-, 18- and 
26-month old 
in male SD 
----- Unaltered for 3-
month old and 
marked increase 
for 18- and 26-
month old 
Increased in  
age-
dependent 
manner  
Increased mainly 
in young animals 
and in less extent 
in olders 
 
(Novelli et al., 
1999) 
Dex i.p. 2 mg/kg b.w. 
for 12 d in 
female SD  
----- Fed moderate 
hyperglycemia 
Fed increase Increased  
 
(Karlsson et 
al., 2001) 
Dex s.c. 100 µg /kg b.w 
for 6 d in non-
pregnant 
Wistar 
Modest decrease 
in GT 
Unaltered Increased Increased (Holness & 
Sugden, 2001) 
Dex s.c. 1 µg b.i.d. for 
4 wk 
Decreased IS Unaltered Increased  Increased (Severino et 
al., 2002) 
Dex oral10 or 100 µg 
/kg b.w. for 8 
wk in male 
SD 
Decreased IS Unaltered Increased for 
both 
----- (Choi et al., 
2006) 
Dex i.p. 0.1, 0.5 or 1 
mg/kg b.w. for 
5 d on Wistar 
Decreased  
IS in all 
Decreased GT 
(0.5 and 1 mg) 
Modest increase 
with high dose 
Dose-
dependent 
increase 
Increased dose 
dependently 
 
(Rafacho et 
al., 2008) 
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GC R Dosing Insulin 
sensitivity (IS) 
Glucose 
tolerance (GT) 
Fasting 
glycemia 
Fasting 
insulinemia 
Insulin secretion Reference 
Dex i.p 0.125 mg/kg 
b.w. for 20 d 
in SD  
Decreased IS Unaltered  Increased  Increased (Novelli et al., 
2008) 
Dex i.p. 0.2 mg/kg b.w.
for 2 d in male 
Wistar 
----- Modest increase Increased Increased (Sood & 
Ismail-Beigi, 
2010) 
Dex i.p. 1 mg/kg b.w. 
for 1, 3 or 5 d 
in male 
Wistrar 
Decreased  
IS - 3 and 5 d  
Decreased  
GT – 5 d 
Tendency 
towards on 5 d 
Time-
dependent 
increase 
Increased  in all (Rafacho et 
al., 2011) 
R; route, b.i.d.; twice a day (from Latin bis in die), d; day, Dex; dexamethasone, SD; Sprague-Dawley, ---
--; none 
Table 2. Effects of prolonged GC treatment in normal rats on endocrine pancreas parameters. 
2.2.3. Ex vivo insulin secretion by isolated islets from GC-treated rats 
Islet insulin secretion in response to several stimuli, especially glucose, has been found to be 
reduced (Ogawa et al., 1992; Ohneda et al., 1993), unchanged (Chuthaputti & Fletcher, 1987; 
O'Brien et al., 1991) or increased (Wang et al., 1994; Novelli et al., 1999; Barbera et al., 2001; 
Karlsson et al., 2001; Giozzet et al., 2008; Rafacho et al., 2008; Rafacho et al., 2009; Rafacho et 
al., 2010; Sood & Ismail-Beigi, 2010; Rafacho et al., 2011) in GC-treated rats. The abrogation 
of insulin secretion by glucose is observed in Wistar rats vulnerable to GC treatment (that 
develop a diabetic profile after steroid treatment) (Ogawa et al., 1992) or in a Zucker fatty 
strain (fa/fa) (Ogawa et al., 1992; Ohneda et al., 1993). In islets from these rats, a 
chronological association between reductions in glucose transporter (GLUT)-2 
immunolocalization in β-cells and glucose uptake in islets with the development of 
hyperglycemia is found (Ohneda et al., 1993). The reduction of GLUT2 could however not 
fully explain the total loss of GSIS in these rats if one considers that the remaining β-cells 
with intact GLUT2 distribution maintain a normal insulin response to glucose. These 
findings, if reproduced in humans, speak against the use of GCs in conditions where the 
insulin demand is already increased prior to GC treatment.  
The most prominent functional islet adaptation, when rats are challenged with steroids, is 
the increased insulin response to glucose. This adaptation most likely occurs to compensate 
for GC-induced IR. This enhancement of β-cell function, also observed in humans, is 
anticipated in healthy individuals and guarantees a regular disposition index (the product 
of insulin secretion and peripheral insulin sensitivity). Figure 1 shows an overview of some 
already known mechanisms involved in this enhanced islet function and the proposed 
modes of interference by GC treatment. The β-cell possesses a unique signal transduction 
system dependent on metabolism of fuel stimuli to initiate insulin secretion (Matschinsky, 
1996). Glycolytic and oxidative metabolism accelerates the generation of adenosine 
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triphosphate (ATP). A rise in the cytosolic ATP/adenosine diphosphate (ADP) ratio is 
believed to close metabolically sensitive K+ channels (KATP channels), leading to 
depolarization of the β-cell membrane. This activates voltage-gated Ca2+ channels and 
elevates intracellular Ca2+ concentration ([Ca2+]i), and culminates in the exocytosis of insulin-
containing granules. In addition, elevation of [Ca2+]i activates a number of potentiating 
signaling pathways, including protein kinase A (PKA) and protein kinase C (PKC), which 
amplify insulin release (Nesher et al., 2002). 
 
Figure 1. Insulin secretory process in β-cells from GC-treated rats. The known components involved 
in the adaptive increase in β-cell function after GC treatment are highlighted with a positive signal 
(orange circle), which indicates increased content or activity of the component after GC treatment. Most 
notably, increased glucose metabolism and cholinergic pathway activity cause increased calcium influx 
and insulin secretion. Abbreviations: AC, adenylyl cyclase; Ach, acetylcholine; ADP, adenosine 
diphosphate; ATP, adenosine  triphosphate; cAMP, cyclic adenosine monophosphate; Cx36, connexin 36; 
DAG, diacylglycerol; FFA, free fatty acids; G6P,  glucose-6-phosphatase; Gs. G-coupled stimulatory 
protein; GK, glucokinase; GLUT2, glucose transporter 2; IP3, inositol trisphosphate; M3R, muscarinic 
receptor type 3; NADH, nicotinamide dinucleotide; NAD(P)H, nicotinamide adenonine dinucleotide 
phosphate; PIP2, phosphatidylinositol bisphosphate; PK, pyruvate kinase; PKA, protein kinase A; PKC, 
protein kinase C; PLC, phospholipase C; VDCC, voltage-dependent calcium channel. Modified from 
Nussey & Whitehead, 2001; Endocrinology: An integrated approach, box 2.19 (Nussey & Whitehead, 2001). 
The establishment of any direct GC effects on β-cells under in vivo conditions is difficult, 
since systemic metabolic consequences of GC treatment (e.g., circulating factors changing 
such glucose, NEFA, and other metabolites and hormones) probably interfere with GC-
mediated changes in β-cell function (van Raalte et al., 2009). Islets isolated from GC-treated 
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rats have enhanced glucose responsiveness (Novelli et al., 1999; Barbera et al., 2001; 
Karlsson et al., 2001; Rafacho et al., 2008; Sood & Ismail-Beigi, 2010), higher glucose 
sensitivity (lower EC50 values to glucose) (Giozzet et al., 2008; Rafacho et al., 2008), and 
exhibit pronounced first and second phase insulin secretion in response to glucose (Rafacho 
et al., 2008; Rafacho et al., 2011). The glycolytic components seem not to be involved in such 
augmented insulin response, since mRNA and protein contents of GLUT2, glucokinase (GK) 
and pyruvate kinase (PK) are unaltered in islets from DEX-treated rats (Rafacho et al., 2010; 
Sood & Ismail-Beigi, 2010). However, these data do not exclude that GK and/or PK activities 
may be elevated since enzymatic activities have not been measured directly. Indirect 
determination of reduced nicotinamide adenine dinucleotide phosphate [NAD(P)H] 
generation and mitochondrial function, by NAD(P)H autofluorescence and rhodamine 123 
fluorescence, respectively, indicate increased glucose metabolism in islets from GC-treated 
rats (Rafacho et al., 2010). These authors did not determine the islet ATP content but found 
augmented [Ca2+]i in response to glucose that was not a result of elevated basal [Ca2+]i. The 
glucose-induced elevation in [Ca2+]i appeared not to involve significant changes in KATP 
channels or voltage-gated Ca2+ channels response, since islets from DEX-treated rats 
perfused with high K+ or tolbutamide did not show higher [Ca2+]i compared to control islets. 
These data give a clear indication of enhanced glucose sensitivity in islets from GC-treated 
rats. The amplifying pathway of GSIS, which involves activation of Ca2+-dependent kinases, 
is altered in GC-treated rat islets. DEX-treated rats have high islet content of phosphorylated 
PKCα protein that is associated with increased number of docked insulin-containing 
granules (Rafacho et al., 2010) as well as higher insulin secretion in response to the PKC 
activator phorbol 12-myristate 13-acetate (PMA) (Rafacho et al., 2010). In addition, the 
cholinergic pathway, mediated by phospholipase C (PLC)/inositol triphosphate (IP3) / PKC 
signals, contributes to such an increase in β-cell function in GC-treated rats. The insulin 
secretion and [Ca2+]i are increased in response to cholinergic stimulation in islets from GC-
treated rats (Rafacho et al., 2008; Rafacho et al., 2010). It is known that DEX-treated rats 
exhibit higher islet content of muscarinic receptor type 3 (M3R) and PLC β1. These islets are 
less responsive to cholinergic blockade during dynamic insulin secretion experiments in the 
presence of stimulatory concentrations of glucose and cholinergic agonists (Angelini et al., 
2010). Corroborating this hypothesis, vagus dennervation partially abrogated the 
hyperinsulinemic profile in DEX-treated rats (Angelini et al., 2010). Notwithstanding the 
important role of glucose metabolism and cholinergic signals for the increased β-cell 
function in GC-treated rat models, the involvement of non-glucidic insulin secretagogues 
(amino acids and NEFA) (Novelli et al., 1999; Rafacho et al., 2010), non-metabolic signals 
(Rafacho et al., 2010), cyclic adenosine monophosphate (cAMP)-dependent protein kinases 
(Rafacho et al., 2010), and gap junctional intercellular communications (formed by connexin 
36 protein in β-cells) (Rafacho et al., 2007) are also observed in these rats. All this 
information indicates that several factors are involved in augmentation of the insulin 
secretion response in islets isolated from GC-treated rats. It was recently demonstrated that 
insulin hypersecretion precedes any discernible indication of IR in DEX-treated rats 
(Rafacho et al., 2011). After 24 hours of DEX administration, rats become hyperinsulinemic 
and exhibit increased GSIS concomitant with normal blood glucose values, normal 
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lipidemia, and without any evidence of IR. As the treatment continues, IR unfolds and islets 
become more responsive to glucose. A possible explanation for the early increase of insulin 
release may reside in central nervous system (CNS) signals. Direct administration of DEX to 
the CNS appears to increase parasympathetic system activity, resulting in augmented 
plasma insulin levels (Zakrzewska et al., 1999). This observation is in agreement with the 
results obtained with ganglionic antagonist infusion in DEX-induced IR and insulin 
hypersecretion in human volunteers as described before (Ahrén, 2008). Of note, all these 
altered ex vivo islet responses are transitory and reversible after discontinuation of GC 
treatment (Karlsson et al., 2001; Wierup et al., 2006; Rafacho et al., 2010); however, great 
caution is required in translating these observation to human applications. 
2.2.4. Structural changes in pancreatic islets in response to GC treatment in rats 
Compensatory islet hypertrophy in response to GC treatment in vivo was first described in 
the eighties (Jonas et al., 1983; Tomita et al., 1984; Zwicker & Eyster, 1993). The mechanisms 
involved in islet hypertrophy were elucidated several years later (Rafacho et al., 2007; 
Rafacho et al., 2008; Rafacho et al., 2009). Activation of cell cycle progression machinery in 
normal rats in response to GC treatment is probably associated with the degree of IR that in 
turn is correlated to dose and/or duration of GC administration (Rafacho et al., 2009; 
Rafacho et al., 2011) and does not involve direct effects of GCs on β-cells, since it is known 
that steroids inhibit β-cell proliferation and promote β-cell death in vitro (Weinhaus et al., 
2000; Liu et al., 2006; Ranta et al., 2006; Nicoletti-Carvalho et al., 2010). Instead, increased 
levels of circulating hormones and/or substrates, such as glucose, insulin, insulin-growth 
factor (IGF)-1, glucagon-like peptide (GLP)-1 and other circulating growth factors, may be 
responsible for promotion of β-cell growth in GC-treated rats [for review see references 
(Heit et al., 2006) and (Vasavada et al., 2006)]. β-cell proliferation is significantly increased 
after 5 days of DEX treatment in a positive reciprocity with steroid dose (1.0 mg/kg > 0.5 
mg/kg b.w.), but absent when IR is modest as in 5-days 0.1 mg/kg b.w. DEX treatment 
(Rafacho et al., 2009). The same correlation between IR degree and β-cell proliferation is 
observed when analyzed during time-course studies. After 1 day GC treatment, no changes 
in β-cell proliferation are observed and IR is not discernible. However, as GC treatment 
continues (3 to 5 days), IR develops and and the increase in β-cell proliferation is correlated 
with the degree of IR (Rafacho et al., 2011). With some combinations of GC treatment, β-cell 
hypertrophy is also observed (Choi et al., 2006; Rafacho et al., 2009). Thus, β-cell hypertrophy 
and/or proliferation accounts for increased β-cell mass upon GC treatment (Choi et al., 2006; 
Rafacho et al., 2010, Rafacho, 2009). This augmentation in β-cell mass is associated with 
increased islet protein content of insulin receptor substrate (IRS)-2, phosphorylated serine-
threonine kinase (PKB), cyclin D (Cd)-2, cyclin-dependent kinase (Cdk)-4, phosphorylated 
retinoblastoma protein (pRb), but not with activation of extracellular-regulated kinase (Erk)-
1/2 (Rafacho et al., 2008; Rafacho et al., 2009). Considering that plasma insulin concentrations 
increase in a GC dose- and/or time-dependent manner, it is conceivable that circulating insulin 
is one candidate mediator of β-cell growth. In addition, these GC-induced IR models do not 
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exhibit changes in β-cell death (Rafacho et al., 2009; Rafacho et al., 2010) and almost all 
morphological changes are transitory and reversible after 10 days discontinuation of steroid 
treatment, suggesting an unacknowledged plasticity in the regulation of β-cell growth. 
Taken altogether, like in humans, rats subjected to prolonged steroid treatment develop 
increased β-cell function as an adaptive compensation to surpass GC-induced IR. 
Susceptible strains; however, are prone to develop β-cell dysfunction that results in 
impaired glucose homeostasis. The β-cell growth accompanies the requirement for insulin in 
a direct relation with IR and demonstrates a great plasticity of endocrine pancreas to face 
fluctuations in metabolic demand. 
2.3. Functional and structural changes in pancreatic islets in GC-treated mice 
Less is known about in vivo GC effects in normal mice than in rats. Acute administration of 
hydrocortisone (300 mg/kg b.w.) to male Swiss mice inhibits insulin secretion (Longano & 
Fletcher, 1983) with reduced insulinogenic index already after 1 h of steroid administration. 
The insulin secretion in response to i.v. glucose load is also suppressed in this hydrocortisone 
model and may involve increased sympathetic drive. In response to prolonged DEX treatment 
(2½ days, with a dose equivalent to 1 mg/kg b.w.) islets isolated from normal adult mice show 
a modest decrease in insulin response to either 5.5 mM or 16.7 mM glucose. However, when 
the increment in insulin release between 5.5 mM and 16.7 mM glucose is calculated, a higher 
insulin response in DEX-treated animals as compared to vehicle treated mice is noted. As 
blood glucose and insulinemia were not determined in this experiment (Ling et al., 1998), 
which could indicate any deleterious GC effects on glucose homeostasis, caution should be 
exerted as to making conclusions about GC effects in normal mice. 
Most of the data obtained with mouse models come from studies in genetically obese, leptin 
deficient mice (ob/ob) that display IR (Table 3). Obese mice treated with 25 µg DEX for 1 to 2½ 
days (at a dose equivalent to 0.5 mg/kg b.w.) exhibit increased islet glucose cycling 
(dephosphorylation of glucose-6-phosphate [G6P] to glucose by glucose-6-phosphatase 
[G6Pase]) both at 5.5 mM and at 16.7 mM glucose, but at the same time unaltered islet glucose 
oxidation and utilization. These results are associated with diminished or inhibited GSIS 
(Figure 2) (Khan et al., 1992; Khan et al., 1995). In an attempt to extrapolate these observations 
and determine whether they are caused by direct islet effects of GC in vivo, a transgenic mouse 
that overexpresses the GR specifically in β-cells was generated (Delaunay et al., 1997). These 
mice also displayed increased glucose cycling, mild glucose intolerance, decreased 
insulinogenic index and GSIS, but remained normoglycaemic (Delaunay et al., 1997; Ling et al., 
1998). DEX treatment increased glucose cycling and the impairment of GSIS in this transgenic 
model. Again, islet glucose utilization and oxidation in the transgenic mice were comparable 
to those in control animals, demonstrating that the enhanced glucose flux trough G6Pase does 
not alter glucose utilization. Moreover, glucose cycling is neglible in normal rodents (≈ 3%) 
and appears not to be a plausible explanation of the inhibitory effect of insulin release by DEX 
(Khan et al., 1992). The impact of direct GC effects in β-cells is better demonstrated in 11- to 12-
month-old transgenic mice (GR-overexpressing at β-cells). At this age, mice developed 
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hyperglycemia and hypoinsulinemia, glucose intolerance, borderline IR (not significant), and 
decreased GSIS both in vivo and ex vivo. The reduction of GSIS was abolished after incubation 
of islets with an antagonist of α2-adrenergic receptor (α2-AdrR) that is associated with 
increased islet mRNA and α2-AdrR density. No alterations in GLUT2 distribution or in β-cell 
apoptosis were detected (Davani et al., 2004). Thus, the adrenergic signals (Figure 2) may 
participate in this impaired β-cell response caused by acutely or for more prolonged periods 
GC treatment. The transgenic approach revealed valuable information regarding the specific 
GC effects upon β-cells, but it does not take into account the overall metabolic GC effects. 
Studies conducted in adult mice treated with GCs, where peripheral effects of GCs are 
preserved, have shown increased circulating insulin levels when IR is apparent, but 
investigation of β-cell function and structure was not done (Thomas et al., 1998; Karatsoreos et 
al., 2010). In summary, acute GC treatment induces reduction of β-cell function in mice and 
this effect is accelerated in susceptible mice (old, obese or GR-overexpressing), which is in 
agreement with the deleterious effects of GCs on β-cell function known from studies with 
predisposed human individuals and in certain rat models. Nevertheless, GC effects on β-cell 
function and growth in normal mice are not known and merit further investigation. 
 
 
GC 
R Dosing Insulin 
sensitivity (IS) 
Glucose 
tolerance (GT)
Fasting 
glycemia 
Fasting 
insulinemia 
Insulin 
secretion 
Reference 
Dex i.p. 1 or 2 d of 25 µg 
for ob/ob mice 
weighing around 
50 g 
----- Unaltered in 
both 
Unaltered in 48 
h, but not 
determined  
in 24 h  
Decreased 
(24 h) or 
inhibited  
(48 h)  
(Khan et 
al., 1992) 
Dex i.p. 2 ½ d of 25 µg for 
ob/ob mice 
weighing more 
than 50 g 
----- ----- ----- ----- (Khan et 
al., 1995) 
----- ----
- 
Transgenic adult 
mice  
Mild decrease 
in GT 
Unaltered Modest decrease 
only in 1 from 2 
groups analyzed
Decreased 
 
(Delaunay 
et al., 1997) 
Dex i.p. 25 µg for 2 ½  d in 
normal or 
transgenic adult 
weighing around 
25 g  
----- Unaltered 
between 
transgenic 
and controls 
----- Decreased 
in normal 
and 
transgenic 
 
(Ling et al., 
1998) 
----- ----
- 
12-15 month-old 
transgenic mice 
Tendency 
towards 
decrease in IS 
Decreased GT 
Increased Decreased Decreased  (Davani et 
al., 2004) 
d; day, Dex; dexamethasone, R; route, Transgenic; glucocoticoid receptor overexpression under rat 
insulin promoter 1, -----; none 
Table 3. Effects of prolonged GC treatment in ob/ob or transgenic mice on endocrine pancreas 
parameters. 
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Figure 2. Insulin secretory process in β-cells from GC-treated mice. The known components involved 
in the reduced β-cell function are highlighted with a positive signal (orange circle), which indicates 
increased content or activity of the component after GC treatment. Most notably is the increased 
adrenergic activity that seems to inhibit insulin secretion. Abbreviations: AC, adenylyl cyclase; Ach, 
acetylcholine; ADP, adenosine diphosphate; ATP, adenosine trisphosphate; cAMP, cyclic adenosine 
monophosphate; DAG, diacylglycerol; G6P,  glucose-6-phosphatase; Gi, G-coupled inhibitory protein; 
GK, glucokinase; GLUT2, glucose transporter 2; IP3, inositol trisphosphate; M3R, muscarinic receptor 
type 3; NADH, nicotinamide dinucleotide; NAD(P)H, nicotinamide adenonine dinucleotide phosphate; 
PIP2, phosphatidylinositol bisphosphate; PK, pyruvate kinase; PKA, protein kinase A; PKC, protein 
kinase C; PLC, phospholipase C; VDCC, voltage-dependent calcium channel. Modified from Nussey & 
Whitehead, 2001; Endocrinology: An integrated approach, box 2.19 (Nussey & Whitehead, 2001). 
2.4. Direct glucocorticoid effects on insulin secretion and β-cell growth in islets 
and β-cell lines  
In vitro, as in vivo, it is difficult to determine with accuracy the specific factors involved in 
the GC effects on β-cell function. This is because in vitro culture does not mimic perfectly the 
metabolic milieu of an intact system in vivo. For example, the timing, duration and level of 
exposure to GC compounds, the concentration range of serum and/or glucose in the culture 
medium, the concentration and variety of insulin secretagogues chosen, and the β cell 
(isolated islets, dispersed islet β-cells, β-cell lines) and species (human, hamster, rat or 
mouse islets) vary (Santerre et al., 1981; Lambillotte et al., 1997; Myrsén-Axcrona et al., 1997; 
Fabregat et al., 1999; Jeong et al., 2001; Shao et al., 2004; Arumugam et al., 2008; Swali et al., 
2008; Roma et al., 2011). Despite the repercussions of these variables, in vitro insights have 
been of great importance to elucidate the direct effects of GCs on insulin secretion. 
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2.4.1. Acute GC effects 
Rodent-derived islets or dispersed β-cells have diminished or inhibited insulin response to 
non-metabolizable and metabolizable secretagogues, especially to glucose, both after acute 
(minutes) (Billaudel & Sutter, 1979; Barseghian & Levine, 1980) or prolonged (hours to days) 
GC exposure (Lambillotte et al., 1997; Weinhaus et al., 2000; Jeong et al., 2001; Zawalich et 
al., 2006). In the presence of three different concentrations (physiological and 
supraphysiological), corticosterone does not affect rat islet insulin secretion under basal 
glucose conditions, whereas, in response to 16.7 mM glucose, insulin release is inhibited. This 
study emphasizes that physiological corticosterone concentrations (0.02 and 0.2 mg/L) have 
strong negative impact on insulin secretion (Billaudel & Sutter, 1979). In the same trend, it was 
shown that cathecolaminergic signals may play a role in this process, since phentolamine, an 
α-AdrR blocking agent, ameliorated the strong inhibitory effect of corticosterone on insulin 
release (Barseghian & Levine, 1980). This immediate negative effect of corticosterone on 
insulin release is not reproduced by the synthetic GC DEX in isolated mouse (Lambillotte et 
al., 1997) or rat islets (Zawalich et al., 2006). Thus, acute GC effects on insulin release appear to 
be more evident with natural corticosterone used at physiological concentrations. 
2.4.2. Hours to days GC effects 
The inhibition of insulin secretion by GCs begins after 3 to 6 hours (Lambillotte et al., 1997; 
Weinhaus et al., 2000; Zawalich et al., 2006). The mechanisms by which this occurs are not 
completely understood, but several components are already identified as shown in a 
schematic overview and the proposed loci of interference by GCs in Figure 3. Details 
regarding GC compounds used, concentrations, duration of treatment, and main effects on 
β-cell function are described in Table 4. The GC-induced reduction in GSIS could not be 
attributed to decreases in insulin content since it was unchanged or augmented (Pierluissi et 
al., 1986; Gremlich et al., 1997; Lambillotte et al., 1997; Zawalich et al., 2006), although 
reduction was also observed under certain conditions (Jeong et al., 2001). It has been shown 
that presence of DEX in islet or β-cell culture medium induces reduction (Gremlich et al., 
1997) or no change (Shao et al., 2004) in GLUT 2 protein content, decrease in β-cell GK (Shao 
et al., 2004) and pyruvate dehydrogenase (PDH) (Arumugam et al., 2010) activities, and 
increased pyruvate dehydrogenase kinase (PDK)-2 mRNA content (Arumugam et al., 2010). 
Despite alterations of these proximal metabolic components, the failure of β-cells’ response 
to glucose does not appear to involve a defect in the recognition of glucose, because no 
changes in the rate of glucose oxidation (Lambillotte et al., 1997; Zawalich et al., 2006), 
oxygen consumption (Ortsäter et al., 2005), NAD(P)H production (Lambillotte et al., 1997), 
or [Ca2+]i (Lambillotte et al., 1997) have been observed. There are controversies related to 
Ca2+ influx in response to glucose or non-glucidic stimuli (Myrsén-Axcrona et al., 1997; 
Koizumi & Yada, 2008), but in spite of elevation or reduction in Ca2+ influx, there is 
consensus that Ca2+ oscillations are impaired, which may harm the distal events of secretion 
dependent of finely tuned Ca2+ handling. 
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GC Dose and period, and β-cell 
source 
Main results Reference 
Cort 0.02, 0.2 or 20 mg/l along 
first min in isolated rat islets
With 4.2 mM glucose, Cort did not affect IS, but with 
16.7 mM glucose IS was inhibited by the three Cort 
concentrations tested during static incubation, and 
by the two physiological during islets perifusion 
(Billaudel & 
Sutter, 1979) 
Cort Physiological Cort 
concentrations along first in 
rat pancreas 
Acutely inhibit the IS induced by both glucose and 
arginine. Phentolamine, an α-adrenergic blocking 
agent, diminished the strong inhibitory effect of Cort 
on IS  
(Barseghian 
& Levine, 
1980) 
Dex 0.1-1.0 µM for 6, 48 or 96 h 
in hamster β-cell line (HIT) 
Inhibited the IS to the culture medium after 48 or 96 
h, but not to 6 h  
(Santerre et 
al., 1981) 
Dex 
 
 
Pred 
 
Hydr 
0.063, 0.63 or 6.3 µM for 1, 2 
or 3h in rat islets 
 
No alteration at 2 mM glucose, but reduced GSIS (20 
mM) when cultured with 6.3 µM Dex for 1, 2 or 3h 
or 2 h with 0.063 µM or 630 µM for  islet culture. The 
reduced GSIS under 6.3 µM for 2 h culture was also 
seen with 7.5, 10, 12.5, 15, 20 and 30 mM glucose. 
These responses were re-established after 4 h. Pred 
and Hydr also induced decreased GSIS and none of 
these drugs elicit a decrease in islet insulin content  
(Pierluissi et 
al., 1986) 
Dex 
Pred 
Hydr 
24 h in HIT-T15 or RIN-5AH 
cells 
Dex, Pred and Hydr induced an increase of α2-AdrR 
in HIT cells that was prevented by the GR antagonist 
RU38486. 1µM Dex also induced increased 
expression of receptor in RIN-5 cells 
(Hamamdzic 
et al., 1995) 
Dex 1 µM for 18 h in mouse islets Dex had inhibitory effect from the 3rd h incubation. 
Cultured islets in presence of Dex 1 µM had higher 
insulin content than control and the reversibility of 
GSIS in islets treated with 0.25 µM dex was observed 
after 3 h of DEX discontinuation. 20 mM glucose in 
the medium or the presence of KIC did not change 
the inhibitory effect of Dex; however, PMA, cAMP 
or inhibition of α2-AdrR was able to attenuate or 
reversed the negative action of 18 h 1 µM Dex. The 
presence of pertussis toxin abolished the negative 
effect of Dex. IS continues inhibited even after 
stimulation with tolbutamide, high glucose and 
diazoxide. Glucose oxidation and NAD(P)H were 
similar between both islet groups in presence of 3 or 
15 mM glucose. Dex islets had reduced response 
under high glucose during the dynamic protocol and 
the pattern of calcium oscillations were changed in 
Dex islets. IS and calcium influx were also lower in 
response to Cch in Dex islets 
(Lambillotte 
et al., 1997) 
Dex 1 µM for 48 h in rat islets Dex induced a decrease in GLUT2 protein 
expression in a glucose-dependent manner that is 
blunted by RU486. Addition of palmitic acid had no 
additive effect on the reduction of GLUT2 protein 
(Gremlich et 
al., 1997) 
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GC Dose and period, and β-cell 
source 
Main results Reference 
expression compared to Dex alone. Dex induced an 
inhibition of GSIS that was also evidenced by 
palmitic acid alone or in combination with Dex. The 
total islet insulin content were decreased in response 
to the palmitic acid whereas were increased by Dex. 
The effect of Dex was inhibited by RU486  
Dex 100 nM for 1 to 5 d in 
RINm5 cells 
Dex induced an increase in NPY mRNA expression 
in a time-dependent manner. It also induced an 
increase in NPY immunoreactivity. Dex treated cells 
had less IS to the medium, whereas increased NPY 
release. IS in several conditions was reduced in cells 
treated with Dex. The D-glyceraldehyde-induced 
raise in [Ca2+]i was impaired after Dex treatment. 
Also, the increase in cytosolic calcium when 
stimulated with KCl was lowered by Dex. 
(Myrsén-
Axcrona et 
al., 1997) 
Dex 1 nM – 1 µM during 6 d 
culture in 5 d neonate rat 
islets 
After 6 d culture, 10 nM  to 1 µM Dex markedly 
reduced the content of IS to the medium in control 
and in PRL-treated islets. Dex (100 nM) exerted its 
effects since the 1st day culture and abolished the 
positive effects of PRL when incubated together with 
PRL. Six d of 100 nM Dex inhibited the IS from 2.8 to 
7.2 or 13.5mM glucose alone or in combination with 
PRL, but did not induce a decrease in total islet 
insulin content 
(Weinhaus et 
al., 2000) 
11-
DHC 
50 or 500 nM 11-DHC for 20 
h in ob/ob mouse islets 
Incubation of β cells in the presence of 11-DHC led 
to a dose-dependent inhibition of IS. Inhibition of 
11β-HSD1 activity by carbenoxolone reversed 
inhibition of IS  
(Davani et 
al., 2004) 
Dex 1, 10 or 100 nM for 1 to 6 h 
in rat islets 
IS decreased in a time- and dose-dependent manner 
being significant already after the 1st  h incubation 
within 10 or 100 nM Dex, but not for 1 nM until the 
6th h culture. The 1st, but not 2nd phase GSIS were 
reduced in response to 10 or 100 nM Dex (Dex were 
exposed only during perifusion). The islet insulin 
content was higher in islets from 1, 10 and 100nM 
culture after 1 h treatment and reduced for only 100 
nM after 6 h. After 6, but not 1 h, 10 and 100 nM Dex 
reduced the pre-proinsulin mRNA content.  
(Jeong et al., 
2001) 
Dex 50 ng/ml -1ug/ml for 24 h in 
MIN6 cells 
Dex from 50 ng to 1mg/ml inhibited IS to the culture 
medium after 24 h. Dex (100 nM) inhibited GSIS in a 
time-dependent fashion from the 6 h to 48 h 
treatment. Dex (100nM) did not change GK protein 
content, but inhibited GK activity from the 6 h ahead 
and did not affect the GLUT2 protein content during 
long term treatments. Even in response to KIC Dex-
treated cells had inhibited IS. Dex induces a 
(Shao et al., 
2004) 
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GC Dose and period, and β-cell 
source 
Main results Reference 
reduction in cAMP content that was prevented by 
the presence of the inhibitor of the PDE. The increase 
in PDE activity was confirmed after Dex treatment 
 Dex 100 nM for 4h in mouse 
islets or INS1 cells. For IHC, 
mice received 1 injection of 
10 mg/kg b.w. Dex and 
killed 24 h after 
After 4 h 100 nM Dex it was observed increased 
mRNA expression of KV-1.5 (repolarizing K 
channel). This was associated with increased SGK1 
mRNA and protein expression in a time-dependent 
manner (INS1 cells) and immunoreactivity in mice 
islet pancreas. All analysis in cells was abrogated by 
the presence of RU486. The activity of KV-1.5 channel 
was increased after Dex treatment and mediated by 
SGK1, that was associated to reduced [Ca2+]i peaks in 
response to glucose. The inhibited GSIS in DEX-
treated INS1 cells and mouse islets were reverted by 
the presence of K channel inhibitors TEA and MSD. 
Presence of diazoxide and high KCL also reversed 
the insulin secretion in DEX-treated INS1 cells. SGK1 
knockout mice did not present the same reduction in 
GSIS. 
(Ullrich et al., 
2005) 
11-
DHC 
5, 50 or 500 nM 11-DHC for 
48 h in ob/ob mouse islets 
Islets from the ob/ob mouse contained almost 
twofold more 11β-HSD1 protein than islets from the 
C57BL/6J mouse. When islets from ob/ob mice were 
cultured with 50 nM 11-DHC, the 11β-HSD1 levels 
doubled compared with islets cultured in the 
absence of DHC. Selective inhibition of 11β-HSD1 
attenuated DHC-induced increase in 11β-HSD1 
levels, as did an antagonist of the GR. In 
individually perfused ob/ob mouse islets, early and 
late phases of GSIS were dose-dependently inhibited 
by 11-DHC. Whereas inclusion of 11β-HSD1 
inhibitors restored, addition of the GR antagonist 
attenuated the DHC-mediated inhibition of GSIS. 
(Ortsäter et 
al., 2005) 
Dex 100 nM for 3 d in BRIN-BD 
11 cells  
DEX-treated cells lacked responsiveness to glucose 
and membrane depolarisation, and both PKA and 
PKC secretory pathways were desensitised.  
(Liu et al., 
2006) 
Dex 1 µM concomitant or for 3 h 
previous culture in rat islets 
Dex (included in the perifusion solution) has no 
effect on GSIS. Previous incubation with Dex 
markedly decrease the 1st  and the 2nd  phases IS 
under 15 mM glucose. This result was not associated 
to reduction in insulin content or glucose oxidation. 
IS was also reduced in response to TPA or KCl in 
Dex islets. Dex also reduces the agonist-induced 
inositol phosphate accumulation in islets, but did 
not change the protein content of 5 different PLC 
protein isoforms. Significant reductions in glucose-
induced IP accumulation accompanied the reduction 
(Zawalich et 
al., 2006) 
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GC Dose and period, and β-cell 
source 
Main results Reference 
in GSIS. Islet exposed to Dex for 3 h contained 
protein amounts of PLC isoforms and PKCα 
comparable to control islets. No impairment in label 
incorporation, used to monitor PLC activation under 
these conditions, was observed 
Dex 
 
Cort 
10 - 500 ng/ml Cort or 
1µg/ml Dex for 3 d in 
dispersed rat β-cells 
Cort (10 to 500 ng/ml) decreased the Ca2+ response to 
glucose in β-cells, which were GR dependent 
(Ru486). Dex (1ug/ml, but not 10 ng/ml) reduced 
Ca2+ response to glucose in β-cells. Co-incubation of 
Cort with aldosterone revealed a protective role for 
aldosterone.  
(Koizumi & 
Yada, 2008) 
Dex 100 nM for 1 d in INS1 cells Dex upregulated the expression of SGK1 in INS1 
cells and increased plasma membrane Na+/K+ 
ATPase activity.  
(Ullrich et al., 
2007) 
Dex 
Hydr 
100 nM Dex for 20 h in INS1 
cells 
Dex upregulated FoxO1, PGC1α, PPARγ, CPT-1, 
and UCP-2 mRNAs inhibited GSIS in INS1 cells. 
Hydr had similar effects.  
(Arumugam 
et al., 2008) 
Dex 
 
Cort 
 
11-
DHC 
For 2 h in mouse islets 11β-HSD1 co-localized with glucagon in the 
periphery of murine and human islets, but not with 
insulin or somatostatin. Incubation (2 h) of islets 
from normal mice to Dex resulted in a dramatic 
reduction of IS in a dose-dependent manner that was 
GR-dependent (RU486). Cort (50 nM) and 11-DHC 
(11β-HSD1-mediated) induced inhibition of GSIS. 
Dex, Cort and 11-DHC also decreased glucagon 
release, and the effect of 11-DHC was partially 
prevented by enzyme inhibitor 
(Swali et al., 
2008) 
Dex 100 nM Dex for 48 h in rat 
islets or 3 h in 100 nM Dex 
in RINm5F cells 
Dex time- and dose-dependently increased total 
FoxO1 mRNA and protein content together with 
decreased phosphorylation levels in RINm5F cells as 
well as islets. Presence of IGF-1 reverses these 
changes. Dex induced a nuclear localization of 
FoxO1. The mRNA content of FoxO1 were reduced 
in RINm5F cells after knockdown, which resulted in 
increased mRNA and protein levels of the PDX1 in 
cells cultivated in presence of Dex. Islets infected 
with Adenovirus-Foxo1-SiRNA had decreased 
FoxO1 protein content and had ameliorated GSIS.  
(Zhang et al., 
2009) 
Dex 100 nM Dex for 24h in rat 
islets or INS1 cells 
Dex did not alter PC protein or activity levels. Dex 
reduced PDH activity and had increased PDK2 
mRNA in islets and INS-1 cells. 
(Arumugam 
et al., 2010) 
Dex 1 µM for 3 d in rat islets Dex increased the ROS, decreased viability and 
GSIS, but did not change calcium handling. Dex 
treatment also resulted in reduction of catalase and 
synaptotagmine VII mRNA content. 
(Roma et al., 
2011) 
Pred Most effects achieved by 700 PRED inhibited GSIS and decreased both PDX1 and (Linssen et 
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GC Dose and period, and β-cell 
source 
Main results Reference 
nM after 20 h in INS1 cells insulin expression, leading to a marked reduction in 
cellular insulin content. These PRED-induced 
detrimental effects were GR-mediated (RU486). 
PRED induced a GR-mediated activation of both 
ATF6 and IRE1/XBP1 pathways but was found to 
reduce the phosphorylation of PERK and its 
downstream substrate eIF2α. These modulations of 
ER stress pathways were accompanied by 
upregulation of calpain 10, increased cleaved 
caspase 3 and β-cell apoptosis. 
al., 2011) 
Dex; dexamethasone, Pred; prednisolone, Cort; corticosterone, GSIS; glucose-stimulated insulin 
secretion, Hydr; hydrocorticosterone, IS; insulin secretion, 11-DHC; 11-hydroxysteroid dehydrogenase 
Table 4. Effects of GCs in vitro on insulin secretion from islets, dispersed islet β-cells or β-cell lines. 
The insulin secretory dysfunction induced by GCs is not solely restricted to glucose. 
Additional effects may contribute to β-cell dysfunction; impairment of insulin secretion in 
response to α-ketoisocaproate (KIC), tolbutamide, or high K+ concentration after DEX 
treatment is also observed (Lambillotte et al., 1997; Shao et al., 2004; Liu et al., 2006), 
suggesting that factors distal to oxidative phosphorylation (KIC) or metabolism-
independent signals (tolbutamide, high K+) may also be involved in the adverse GC effects 
on the insulin secretory process. DEX may also modulate the inward repolarizing K+ 
currents by upregulating Kv1.5 ion channels as well as Na+/K+ ATPase activity, which appear 
to be mediated through activation of the serum- and GC-inducible kinase (SGK1)-1 (Ullrich 
et al., 2005; Ullrich et al., 2007). These repolarizing currents may limit Ca2+ influx and insulin 
secretion. Downstream steps in the insulin secretory machinery also seem involved in the 
direct GC derangements in β-cells. Zawalich and colleagues (Zawalich et al., 2006) 
demonstrated that DEX pretreatment of rat islets impairs insulin secretion by decreasing 
activation of the PLC/PKC signaling pathway. Moreover, GCs increase the mRNA content 
and α-2AdrR protein density in β-cell lines (Hamamdzic et al., 1995), which may explain the 
lower cyclic adenosine monophosphate (cAMP) levels and attenuated GSIS (Shao et al., 
2004). This latter event is prevented by phosphodiesterase (PDE) inhibitors, which aligns 
well with the upregulated PDE activity by DEX treatment (Shao et al., 2004), although 
controversy remains (Lambillotte et al., 1997). Overall, it appears that GCs act at distal sites 
by diminishing the efficacy of [Ca2+]i on the secretory response by interfering with the 
amplifying pathway, although we cannot exclude their possible negative effects also in the 
mechanisms involved in the rapid first phase insulin secretion (Jeong et al., 2001). The 
interference of GCs in distal sites of the insulin secretory machinery may explain the wide 
spectrum of non-glucose insulin secretagogues being inhibited by GCs (Lambillotte et al., 
1997; Myrsén-Axcrona et al., 1997; Shao et al., 2004; Liu et al., 2006). 
2.4.3. Recent insights into GC effects on insulin secretion in vitro. 
The mRNA content of Forkhead box O (FoxO)-1, peroxisome proliferator activator receptor 
(PPAR)-γ coactivator (PGC)-1α and uncoupling protein (UCP)-2 were upregulated in 
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primary islets after 20 hours of DEX treatment (Arumugam et al., 2008). From these 
observations, it is expected that GC-induced derangements of GSIS can include limited 
production of cellular ATP due to UCP-2 mediated uncoupling of oxidative 
phosphorylation. In addition, increased PGC1-α action, which is associated with elevated fat 
acid oxidation, could induce impairments in insulin secretory process mediated by lack of 
critical lipid mediators involved in the amplifying pathway (Herrero et al., 2005). The GC-
induced increment in total FoxO1 mRNA and protein content, as well as decreased levels of 
FoxO-1 phosphorylation in a rat insulinoma cell line (RINm5F), are time-and dose-
dependent effects and appear to be mediated by the IGF-1 pathway (Zhang et al., 2009). 
Using molecular tools, it was demonstrated that lack of FoxO-1 ameliorates the DEX-
induced impairment of GSIS in β-cell lines, an effect associated with increased levels of 
pancreatic duodenal homeobox (PDX)-1. It was recently demonstrated that presence of 1 µM 
DEX for 3 consecutive days in primary islet culture results in increased generation of reactive 
oxygen species (ROS) (Roma et al., 2011). This study also revealed impaired generation of 
NAD(P)H and reduced GSIS, decreased gene expression of catalase (an antioxidant enzyme) 
and synaptotagmin VII, without alteration in Ca2+ handling. These DEX effects were 
attenuated by N-acetylcysteine (NAC) (Roma et al., 2011), further supporting a role for ROS in 
mediating the cytotoxic effects of GCs. The role of endoplasmic reticulum (ER) homeostasis 
has also been investigated in the context of prednisolone-induced β-cell dysfunction. It has 
been observed that PDX-1 expression and cellular insulin content are reduced by steroid 
treatment (700 nM for 20 hours) in INS-1E cells, which resulted in inhibition of GSIS (Linssen 
et al., 2011). Prednisolone exerts its effects by activation of activating transcription factor 
(ATF)-6 and inositol requiring enzyme (IRE)-1/X-box binding protein (XBP)-1 pathways and 
by decreasing the phosphorylation of protein kinase RNA-activated (PKR)-like eukaryotic 
initiation factor 2α kinase (PERK) and its downstream substrate eukaryotic initiation (eIF2)-α. 
Thus, β-cell dysfunction induced by GCs may be, at least partially, attributed to ER 
dyshomeostasis. These mechanisms are depicted in Figure 3. 
2.4.4. 11β-hydroxysteroid dehydrogenase type 1 and pancreatic islets 
The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyzes the conversion 
of inactive 11-dehydrocorsticosterone (11-DHC) to active corticosterone in rodents and it 
was found in pancreatic islets isolated from ob/ob mice and humans (Davani et al., 2000). 
Incubation of β-cells in the presence of 11-DHC leads to a dose-dependent attenuation of 
GSIS, indicating that cellular activation of 11-DHC may play a role in GC-induced β-cell 
dysfunction and that 11β-HSD1 may potentiate the detrimental effect of GCs on -cell 
function. The protein content of 11β-HSD1 is higher in islets from ob/ob mice, compared to 
C57BL/6J mice, and is further increased when ob/ob islets are cultured in presence of 11-DHC 
(Ortsäter et al., 2005). GSIS in islets from ob/ob mice (but not from normal mice) was dose-
dependently inhibited in presence of 11-DHC, an effect prevented by addition of selective 
11β-HSD1 inhibitors or GR antagonist RU486 (Ortsäter et al., 2005). Recently, it was 
demonstrated that 11β-HSD1 is mainly localized to pancreatic α-cells both in mouse and 
human islets (Swali et al., 2008). In that study, mouse islets had lower glucagon or insulin 
secretion when cultured in presence of DEX, corticosterone or 11-DHC; the effect of 11-DHC 
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was partially prevented by an 11β-HSD1 inhibitor. These data suggest that the ability of α-
cells to generate active GC within the islet impacts on insulin and glucagon secretion by 
three distinct mechanisms: (1) directly at the level of the α-cells, modulating glucagon 
secretion; (2) by decreasing glucagon secretion, which may decrease insulin secretion via 
glucagon receptors expressed on the β-cells and (3) by GC production by α-cells acting in a 
paracrine manner, regulating insulin secretion from neighbouring β-cells (Swali et al., 2008). 
Although the overall conclusion of these findings is that 11β-HSD1 plays a negative role in 
pancreatic -cell function, it should be noted that the complete lack of 11β-HSD1 expression 
in -cells is associated with mild -cell impairment (Turban et al., 2012). In addition, 
moderate -cell specific overexpression of 11β-HSD1 can protect against the diabetogenic 
effects of a high-fat diet. These data lend support to the notion that GCs under certain 
conditions can promote -cell function (Hult et al., 2009; Rafacho et al., 2010). 
 
Figure 3. Direct GC effects on the insulin secretory process in β-cells. The known components involved 
in the direct effects of GCs on the β-cell insulin secretory process are highlighted with a positive signal 
(orange circle – indicates GCs stimulate that action) or negative signal (red circle – indicates GCs inhibit 
that action). Most notably, GCs impair β-cell glucose metabolism, favor repolarizing K+ currents, decrease 
PKA and PKC activation, induce ER dyshomeostasis and increased FoxO1 protein content that altogether 
impair calcium handling and inhibits insulin secretion. Abbreviations: AC, adenylyl cyclase; Ach, 
acetylcholine; ADP, adenosine diphosphate; ATP, adenosine  trisphosphate; cAMP, cyclic adenosine 
monophosphate; Cx36, connexin 36; DAG, diacylglycerol; ER, endoplasmic reticulum; FFA, free fatty 
acids; FoxO1, Forkhead box O; G6P, glucose-6-phosphatase; Gs, G-coupled stimulatory protein; GK, 
glucokinase; GLUT2, glucose transporter 2; IP3, inositol trisphosphate; Kv1·5, voltage-dependent K+ channel; 
M3R, muscarinic receptor type 3; PDX-1, pancreatic duodenal homeobox; PIP2, phosphatidylinositol 
bisphosphate; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C;  SGK-1, serum- and 
glucocorticoid inducible kinase-1; VDCC, voltage-dependent calcium channel, 11-βHSD-1, 11-β 
hydroxysteroid dehydrogenase type 1. Modified from Nussey & Whitehead, 2001; Endocrinology: An 
integrated approach, box 2.19 (Nussey & Whitehead, 2001) and from van Raalte et al., 2009; Eur J Clin 
Invest 2009, 39(2):page 87, Figure 3 (van Raalte et al., 2009). 
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2.4.5. Effects of GCs on β-cell growth in vitro 
It was demonstrated in the seventies that 10 µg/ml DEX exerts inhibitory effects on β-cell 
proliferation in rat pancreatic monolayer cells (Chick, 1973). Several years later, it was found 
that 100 nM DEX negatively interferes with the positive effects of prolactin on β-cell growth 
both in mouse islet cells and INS-1 cells (Weinhaus et al., 2000). The direct effects of DEX on 
β-cell proliferation and β-cell death are GR-mediated and involve the activation of caspase-
3, mitochondrial depolarization, reduction of Bcl-2 protein content, increase of Hsp90 
protein, increased calcineurin activity with attendant elevation in dephosphorylated BAD 
protein levels, and inhibition of IRS-2, PKB and ERK phosphorylations (Ranta et al., 2006; 
Avram et al., 2008; Ranta et al., 2008). Exendin-4, an agonist of GLP-1 receptor, and IGF-1 
protect β-cells against DEX-induced β-cell death. In a recent study, specific knockdown of 
mitogen-activated protein kinase (MAPK) phosphatase (MKP)-1 in RINm5F and MIN6 
insulinoma cells, counteracted the down-regulation of ERK1/2 protein phosphorylation and 
the reduction of β-cell proliferation induced by DEX (Nicoletti-Carvalho et al., 2010). 
Prednisolone also induces β-cell apoptosis in INS-1E cells through up-regulation of calpain 
10 and increased cleavage of caspase-3 (Linssen et al., 2011). In their entirety, these data, 
summarized in Table 5, clearly demonstrate the negative effects of GCs on β-cell growth that 
contrasts to those observed when GCs are administered in vivo. 
 
GC Dose and period, and β-
cell source 
Main results Reference 
Dex 10 µg/ml for 4 d in rat 
pancreatic monolayer cells
Reduced β-cell proliferation (Chick, 
1973) 
Dex 100 nM for 24 h to 3 d in 
rat islet 
Dex alone did not induce significant decrease in β-cell 
proliferation, but markedly decreased the positive effect of 
PRL on β-cell proliferation. Dex for 24 h to 3 d induced an 
increase in islet cell death even in the presence of PRL. 
(Weinhau
s et al., 
2000) 
Dex 100 nM for 1 or 4 d in 
mouse β-cells or INS1 cells
Dex induced mouse islet cells or INS1 cells death that was 
GR-dependent (RU486). Dex induced caspase 3 activity in 
INS1 cells. Dex reduced mRNA and protein content of Bcl-2 
and decrease of mitochondrial polarization. Dex-induced 
cell death was associated to increased calcineurin activity 
and increased BAD dephosphorylation (all reverted by 
RU486 or calcineurin inhibitors). Exendin-4 protects islet 
cells and INS1 cells from Dex-induced cell death via 
activation of PKA. 
(Ranta et 
al., 2006) 
Dex 100 nM for 1 d in INS-1 
cells 
Dex inhibited cell growth, BrdU incorporation and induced 
apoptosis. Dex induced cell death was partially antagonized 
by IGF-1. Despite increased IRS-2 protein, IRS-2 tyrosine 
phosphorylation stimulated by IGF-1 was inhibited by Dex. 
Dex treatment reduced basal PKB phosphorylation. 
However, IGF-1-mediated ERK phosphorylation was 
affected. 
(Avram et 
al., 2008) 
Dex  100 nM for 1 to 4 d in INS-
1 cells 
In INS-1 cells cultured up to 4 d with Dex, the percentage of 
apoptosis increased from 1% to 10.9%. FK506 inhibited dex-
(Ranta et 
al., 2008) 
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GC Dose and period, and β-
cell source 
Main results Reference 
mediated cell death. Apoptosis was significantly higher at 
glucose concentrations that induce [Ca2+]i oscillations than 
at low, non-stimulatory glucose. Calcineurin activity was 
unaltered after Dex treatment. However, Dex treatment 
significantly increased enzyme activity at submaximal, 
physiological Ca2+ concentrations. Dex did not stimulate the 
Ca2+-dependent protease calpain, known to activate 
calcineurin by cleavage. In Dex-treated cells Hsp90 protein, 
a component of the GR known to stimulate calcineurin,was 
increased while calcineurin protein levels were unchanged. 
In immunoprecipitates with calcineurin antibodies, Hsp90 
was only detected in Dex-treated cell homogenates.  
Dex 100nM Dex for 3 d culture 
both for MIN6 or Rin5 cells
Dex reduced phospho-ERK1/2 and increased MKP-1 
expression in RINm5F and MIN-6 cells. Inhibition of 
transduction with cycloheximide and inhibition of 
phosphatases with orthovanadate efficiently blocked DEX-
induced downregulation of phospho-ERK1/2. In addition, 
specific knockdown of MKP-1 with siRNA suppressed the 
downregulation of phospho-ERK1/2 and the reduction of 
proliferation induced by DEX.  
(Nicoletti-
Carvalho 
et al., 
2010) 
Dex; dexamethasone 
Table 5. Effects of GC in vitro on cell growth in islets, dispersed islet β-cells or β-cell lines. 
3. Conclusions 
Collectively, direct effects of GCs on β-cell function in vitro are opposite to those observed 
when the GCs are administered in vivo to healthy individuals (especially humans and rats), 
which does not exclude that in vivo GCs might exert their known negative effects on β-cells, 
e.g. by increasing 11β-HSD1 activity, induce apoptosis and eventually obscure glucose 
sensing. However, based on data summarized herein, it seems clear that these direct effects 
of steroids on the β-cells are overwhelmed by the compensatory adaptations provoked by 
the GC-induced IR in vivo. Whether continuation of GC treatment for long periods (weeks to 
years) in healthy individuals results in impaired β-cell function is still a matter of debate; 
nevertheless, it is reasonable to say that since short treatments in susceptible subjects (obese, 
low-insulin responders, first-degree relatives of patients with T2DM, pregnant, etc) clearly 
demonstrate β-cell dysfunction, great caution should be exerted as to use GC therapies in 
high doses and/or with prolonged duration. The direct effects of GCs are achieved through 
classical ligand-GR mechanisms, since selective inhibition of GR prevents most GC-induced 
impairments of β-cells in vitro (Hamamdzic et al., 1995; Gremlich et al., 1997; Lambillotte et 
al., 1997; Ullrich et al., 2005; Ranta et al., 2006; Koizumi & Yada, 2008; Swali et al., 2008; 
Linssen et al., 2011) and in vivo (Ohneda et al., 1993). The extent of non-genomic actions of 
GCs on insulin secretion is not yet clear. However, rapid effects observed by physiological 
GC concentrations seem to involve sympathetic autonomic signals (Longano & Fletcher, 
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1983), whereas synthetic compounds with GC activity do not elicit acute modifications in β-
cell responses to insulin secretagogues (Lambillotte et al., 1997; Zawalich et al., 2006). The 
real involvement of 11β-HSD1 on pancreatic islets milieu as well as the effects of GCs on 
pancreatic α-cells and its paracrine consequences on pancreatic β-cell function remain to be 
investigated. 
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